Services

Radically accelerating the development of new drugs and vaccines

Mission /

We're collapsing the gap between proof-of-concept and clinical data with an end-to-end solution for preparation and execution of early-phase clinical trials.

We’ve designed general-purpose systems to expedite vaccine and therapeutic candidates, regardless of modality or indication.

/

Maximum Speed /

Our team identifies opportunities to optimize, parallelize, eliminate or automate every step in the process. The result is up to 2-4x faster timelines, for example:

Accelerated manufacturing from projected 2 months to just 2 weeks (4x faster)
Reduced IRT setup time from estimated 6-12 weeks to just 3 weeks (2-4x faster)
Developed EDC documentation in 3 weeks versus industry standard of 8-12 weeks. (>2.5x faster)

by the Numbers /

Our interdisciplinary team combines experience from academic research to late-stage development and approval.

80 trials: Our team has held direct roles across all development phases and many therapeutic areas, including infectious disease, neurology, and oncology.

5 approved drugs: Our team has previous experience bringing drugs through the development process from IND to market launch.

60% advanced degrees: Majority of the team holds an advanced degree including specialization in Organic and Biochemistry, Molecular and Cellular Biology, Immunology and Medicine, as well as interdisciplinary fields.

Get in Touch. Email Kyle Fish our Co-Founder and CTO

k.fish@alvea.bio